

## Current and Soon-to-Be-Approved Regimens Offer High Cure Rates for HCV

Written by Lynne Lederman

A choice of all-oral regimens to treat patients with hepatitis C virus (HCV) is available in the United States, and more are expected to be approved soon. Andrew J. Muir, MD, Duke University Department of Medicine, Durham, North Carolina, USA, reviewed the current regimens and trial data from those that are expected to be approved soon.

Key data on which to base treatment decisions include prior HCV treatment; if it included interferon and ribavirin, a protease inhibitor, or sofosbuvir; and whether these treatments failed. Fibrosis, if present, should be managed. Decompensated cirrhosis might indicate the need for a transplant evaluation.

US Food and Drug Administration-approved all-oral regimens for HCV include treatments for HCV genotypes 1, 2, and 3. There are no approved all-oral regimens for HCV genotypes 4, 5, or 6. For HCV genotype 1, the sustained virologic response (SVR) rates are >90%, which should be considered the benchmark for treatment. Treatment regimens for patients with genotype 1 are summarized in Table 1.

The TURQUOISE-II study [Poordad F et al. *N Engl J Med.* 2014] compared 12 vs 24 weeks of paritaprevir/ritonavir, dasabuvir, ombitasvir, and ribavirin in treatment-naïve and treatment-experienced patients (n=380) with genotype 1 HCV and compensated cirrhosis. The overall SVR was 92% at 12 weeks and 96% at 24 weeks; responses for genotype 1b were 99% and 100%, respectively, and for genotype 1a were 89% and 94%, respectively.

American Association for the Study of Liver Diseases (AASLD)-Infectious Disease Society of America (IDSA) guidelines recommend sofosbuvir and ribavirin for treatment-naïve and peginterferon alpha/ribavirin-resistant, genotype 2 HCV.

Treatment of genotype 3 HCV remains challenging. AASLD-IDSA guidelines recommend sofosbuvir plus ribavirin for treatment-naïve and peginterferon alpha/ribavirin-resistant, genotype 3 HCV. However, in treatment-experienced patients, particularly those with cirrhosis, response rates are low [Zeuzem S et al. AASLD 2013. Abstract 1085]. The addition of ribavirin to sofosbuvir plus ledipasvir improves SVR rates in treatment-naïve (100%, n=26) and treatment-experienced (82%, n=50) patients with genotype 3 HCV, although the SVR rates are lower in patients with (73%, n=22) than without (89%, n=28) cirrhosis [ELECTRON2; Gane EJ et al. EASL. 2014. Abstract O6; Gane EJ et al. AASLD 2014. Abstract 79]. Response rates were 90% (n=101) vs 86% (n=51) for treatment-naïve versus treatment-experienced patients with genotype 3 HCV treated with daclatasvir plus sofosbuvir [ALLY 3; Nelson DR et al. AASLD 2014. Abstract LB-3].

For treatment-naïve and peginterferon alpha/ribavirin-nonresponsive, genotype 3 HCV, AASLD-IDSA guidelines recommend sofosbuvir and ribavirin for patients ineligible for interferon, adding peginterferon alpha for those eligible for interferon. A small study (n=25) suggests that the off-label combination of sofosbuvir plus ledipasvir is an option for genotype 6 HCV [ELECTRON2; Gane EJ, et al. AASLD. 2014. LB-11].

A key message for patients with HCV is that effective therapies are available, and more treatments, including ribavirin-free regimens, are expected to be approved soon.

Peer-Reviewed  
Highlights From

**AASLD:  
The Liver Meeting**

November 7–11, 2014  
Boston, Massachusetts

Table 1. Treatment Regimens for HCV Genotype 1

Regimen	Weeks	Study	Sustained Virologic Response, n/N (%)
<b>Treatment-Naïve, Noncirrhotic</b>			
Sofosbuvir + ledipasvir (HCV RNA < 6 M IU/mL)	8	ION-3 [Kowdley KV et al. <i>N Engl J Med.</i> 2014]	119/123 (97%)
Sofosbuvir + ledipasvir (HCV RNA > 6 M IU/mL)	12	ION-3 [Kowdley KV et al. <i>N Engl J Med.</i> 2014]	206/216 (95%)
Simeprevir + sofosbuvir	12	COSMOS [Olysis Pkg Insert. 2014]	20/21 (95%)
Paritaprevir, dasabuvir, ombitasvir (genotype 1b)	12	PEARL III [Ferenci P. <i>N Engl J Med.</i> 2014]	207/209 (99.5%)
Paritaprevir, dasabuvir, ombitasvir (genotype 1a)	12	PEARL IV [Ferenci P. <i>N Engl J Med.</i> 2014]	97/100 (97%)
Sofosbuvir + daclatasvir	12	[Sulkowski M et al. <i>N Engl J Med.</i> 2014]	41/41 (100%)
<b>Treatment-Naïve, Cirrhotic</b>			
Sofosbuvir + ledipasvir	12	ION-1 [Afdhal N et al. <i>N Engl J Med.</i> 2014]	32/33 (97%)
Simeprevir + sofosbuvir	24	COSMOS [Olysis Pkg Insert. 2014]	10/10 (100%)
Paritaprevir, dasabuvir, ombitasvir, ribavirin	12 to 24	TURQUOISE II [Poordad F et al. <i>N Engl J Med.</i> 2014]	See text.
<b>Treatment-Experienced, Noncirrhotic</b>			
Sofosbuvir + ledipasvir	12	ION-1 [Afdhal N et al. <i>N Engl J Med.</i> 2014]	83/87 (95%)
Simeprevir + sofosbuvir	12	COSMOS [Olysis Pkg Insert. 2014]	20/21 (95%)
Paritaprevir, dasabuvir, ombitasvir, ribavirin	12	SAPPHIRE II [Zeuzem S. <i>N Engl J Med.</i> 2014]	286/297 (95%)
<b>Treatment-Experienced, Cirrhotic</b>			
Sofosbuvir + ledipasvir	24	ION-2 [Afdhal N et al. <i>N Engl J Med.</i> 2014]	22/22 (100%)
Simeprevir + sofosbuvir	24	COSMOS [Olysis Pkg Insert. 2014]	10/10 (100%)
Paritaprevir, dasabuvir, ombitasvir, ribavirin	12 to 24	TURQUOISE II [Poordad F et al. <i>N Engl J Med.</i> 2014]	See text.

HCV, hepatitis C virus; IU, international unit; M, million; mL, milliliter; SVR, sustained virologic response.

- 37th Annual San Antonio Breast Cancer Symposium**  
December 9–13 • San Antonio, Texas, USA
- 50th American Society of Clinical Oncology 2014 Annual Meeting Science & Society**  
May 30–June 3 • Chicago, Illinois, USA
- Acute Cardiovascular Care 2014\***  
October 18–20 • Geneva, Switzerland
- American Academy of Neurology**  
April 28–May 3 • Philadelphia, Pennsylvania, USA
- American Academy of Ophthalmology 2014**  
May 18–21 • Chicago, Illinois, USA
- American Academy of Orthopaedic Surgeons**  
March 11–15 • New Orleans, Louisiana, USA
- American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting & OTO EXPO**  
September 21–24 • Orlando, Florida, USA
- American Association for the Study of Liver Disease**  
November 4–7 • Boston, Massachusetts, USA
- American Association of Diabetes Educators**  
August 6–9 • Orlando, Florida, USA
- American College of Cardiology 47th Annual New York Cardiovascular Symposium\***  
December 12–14 • New York, New York, USA
- American College of Cardiology 63rd Annual Scientific Session & Expo\***  
March 29–31 • Washington, DC, USA
- American College of Chest Doctors**  
October 25–30 • Austin, Texas, USA
- American College of Emergency Physicians (ACEP14)**  
October 27–30 • Chicago, Illinois, USA
- American College of Rheumatology 78th Annual Scientific Meeting**  
November 13–16 • Boston, Massachusetts, USA
- American Congress of Obstetricians and Gynecologists 2014 Annual Clinical Meeting**  
April 26–30 • Chicago, Illinois, USA
- American Diabetes Association 74th Scientific Sessions\***  
June 13–17 • San Francisco, California, USA
- American Heart Association Scientific Sessions 2014\***  
November 15–19 • Chicago, Illinois, USA
- American Orthopaedic Society for Sports Medicine\***  
July 10–13 • Seattle, Washington, USA
- American Psychiatric Association 2014 Annual Meeting**  
May 3–7 • New York, New York, USA
- American Psychiatric Nurses Association**  
October 22–25 • Indianapolis, Indiana, USA
- American Society for Microbiology—54th Interscience Conference on Antimicrobial Agents and Chemotherapy**  
September 5–19 • Washington, DC, USA
- American Society for Radiation Oncology**  
September 14–17 • San Francisco, California, USA
- American Society for Surgery of the Hand**  
September 18–20 • Boston, Massachusetts, USA
- American Society of Anesthesiologists Anesthesiology 2014 (ASA)**  
Oct 11–15 • New Orleans, LA, USA
- The American Society of Hematology**  
December 6–9 • San Francisco, California, USA
- American Society of Nutrition Scientific Sessions & Annual Meeting at Experimental Biology 2014**  
April 26–30 • San Diego, California, USA
- American Society of Plastic Surgeons Plastic Surgery The Meeting 2014**  
October 10–14 • Chicago, Illinois, USA
- American Stroke Association 2014 International Stroke Conference\***  
February 11–14 • San Diego, California, USA
- American Thoracic Society 2014 Annual Meeting\***  
May 16–21 • San Diego, California, USA
- American Veterinary Medical Association**  
July 25–29 • Denver, Colorado, USA
- Cardio Alex 2014\***  
June 10–13 • Alexandria, Egypt
- Caribbean Cardiac Society 29th Caribbean Cardiology Conference 2014\***  
July 23–July 26 • Atlantis, Paradise Island, The Bahamas
- Cardiostim EHRA Europeace 2014**  
June 23–26 • Nice, France
- The Endocrine Society—ICE/ENDO 2014\***  
June 21–24 • Chicago, Illinois, USA
- ESMO World Congress on Gastrointestinal Cancer**  
June 25–28 • Barcelona, Spain
- European Association for the Study of Diabetes 49th Annual Meeting**  
September 15–19 • Vienna, Austria
- European Committee for Treatment and Research in Multiple Sclerosis**  
September 10–13 • Boston, Massachusetts, USA
- European League Against Rheumatism 2014 Annual Congress**  
June 11–14 • Paris, France
- European Lung Cancer Conference**  
March 26–29 • Geneva, Switzerland
- European Society of Cardiology ESC Congress 2014\***  
August 30–September 4 • Barcelona, Spain
- European Society of Cardiology EuroEcho 2014\***  
December 3–6 • Vienna, Austria
- European Society of Hypertension 2014 Annual Scientific Meeting**  
June 13–16 • Athens, Greece
- European Society of Medical Oncology**  
September 26–30 • Madrid, Spain
- European Society Traumatology, Knee Surgery, and Arthroscopy**  
May 14–17 • Amsterdam, The Netherlands
- Heart Failure 34th Annual Scientific Sessions**  
May 17–20 • Athens, Greece
- Heart Rhythm Society 34th Annual Scientific Sessions\***  
May 7–10 • San Francisco, CA, USA
- International Federation of Foot and Ankle Surgery/American Orthopaedic Foot & Ankle Society\***  
September 19–23 • Chicago, Illinois, USA
- Kidney Week**  
November 5–10 • Atlanta, Georgia, USA
- Movement Disorder Society**  
June 9–12 Stockholm, Sweden
- North American Spine Society**  
November 12–15 • San Francisco, California, USA
- Obesity Week**  
November 2–7 • Boston, Massachusetts, USA
- Orthopaedic Trauma Association**  
October 15–18 • Tampa, Florida, USA
- Radiological Society of North America**  
November 30–December 5 • Chicago, Illinois, USA
- The Society for Cardiovascular Angiography & Interventions (SCAI)\***  
May 28–31 • Las Vegas, NV, USA
- Transcatheter Cardiovascular Therapeutics 2014**  
September 13–17 • Washington, DC, USA

\*Proudly produced in official collaboration with the host society